The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low dens...

Descripción completa

Detalles Bibliográficos
Autores principales: Landlinger, Christine, Pouwer, Marianne G., Juno, Claudia, van der Hoorn, José W.A., Pieterman, Elsbet J., Jukema, J. Wouter, Staffler, Guenther, Princen, Hans M.G., Galabova, Gergana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837708/
https://www.ncbi.nlm.nih.gov/pubmed/28637178
http://dx.doi.org/10.1093/eurheartj/ehx260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837708/
https://www.ncbi.nlm.nih.gov/pubmed/28637178
http://dx.doi.org/10.1093/eurheartj/ehx260

Ejemplares similares